株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:アトピー性皮膚炎 - フランスにおける医薬品の予測と市場分析

PharmaPoint: Atopic Dermatitis - France Drug Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 293253
出版日 ページ情報 英文 108 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.81円で換算しております。
Back to Top
PharmaPoint:アトピー性皮膚炎 - フランスにおける医薬品の予測と市場分析 PharmaPoint: Atopic Dermatitis - France Drug Forecast and Market Analysis to 2022
出版日: 2013年11月30日 ページ情報: 英文 108 Pages
概要

アトピー性皮膚炎(AD)治療薬市場は、この10年間は比較的変わらず、飽和状態で推移してきましたが、今後10年間で、初めての生物製剤が登場し、新たな先例を作ると期待されています。

当レポートでは、フランスにおけるアトピー性皮膚炎(AD)治療薬市場について調査分析し、疾病の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などを提供して、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 症状

第4章 疾病の管理

  • 診断
  • 治療の概要
  • フランス
    • 診断
    • 臨床診療

第5章 競合評価

  • 概要
  • 戦略的競合企業の評価
  • 製品プロファイル - 主要ブランド
    • Protopic (tacrolimus)
    • Elidel
    • Cyclosporine
    • その他
  • 製品プロファイル - 認可外
    • Xolair (omalizumab)

第6章 機会とアンメットニーズ

  • 概要
  • アンメットニーズ
  • アンメットニーズのギャップ分析
  • 機会

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
    • Dupilumab (SAR231893/REGN668)
    • フェーズIIパイプライン製品

第8章 市場の見通し

  • 世界の促進要因・障壁
  • フランス

第9章 付録

図表

目次
Product Code: GDHC184CFR

Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.

By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape.

Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US, and the increasing use of pharmacological treatments in the growing markets of India and China.

GlobalData attributes growth in the French market to the high number of prevalent cases of atopic dermatitis in that country, and high physician prescribing rates. In all, these factors will allow France to maintain a strong stance in terms of sales over the rest of the 5EU countries (except Germany) throughout the 10-year forecast period, with atopic dermatitis sales forecast to reach $451.5m in 2022.

Scope

  • Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in France including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in France from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting France Atopic Dermatitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in France

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Diagnosis
  • 4.2. Treatment Overview
  • 4.3. France
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Protopic (tacrolimus)
    • 5.3.2. Elidel
    • 5.3.3. Cyclosporine (numerous generic names)
    • 5.3.4. Other Therapeutic Drug Classes Used in Atopic Dermatitis
  • 5.4. Product Profiles - Off-Label Therapies
    • 5.4.1. Xolair (omalizumab)

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. A Systemic Drug for Severe Recalcitrant Patients
    • 6.2.2. Tests that Stratify Patients and Allow for a Tailored Treatment Approach
    • 6.2.3. A Drug that Effectively Controls Patients' Pruritus
    • 6.2.4. Further Research into the Pathophysiology of Atopic Dermatitis
    • 6.2.5. A Drug that Induces Disease Remission
    • 6.2.6. Improved Quality of Life for Both Patients and their Carers
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Opportunities
    • 6.4.1. Increase Treatment Armamentarium for Severe Recalcitrant Patients
    • 6.4.2. Predictive Tests for Patient Stratification
    • 6.4.3. More Therapeutic Options that Address Patients' Pruritus

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Dupilumab (SAR231893/ REGN668)
    • 7.2.2. Phase II Pipeline Products

8. Market Outlook

  • 8.1. Global Drivers and Barriers
    • 8.1.1. Driver: Anticipated launch of the first biologic for the treatment of moderate to severe disease
    • 8.1.2. Driver: The underserved severe refractory patient segment presents an untapped market opportunity
    • 8.1.3. Driver: A drug that is able to target two or more atopic diseases would gain a foothold in these markets
    • 8.1.4. Driver: Atopic dermatitis presents an attractive patient population for drug developers
    • 8.1.5. Driver: Restoring skin barrier function remains a key goal of disease management, meaning a continued need for moisturizers and topical agents
    • 8.1.6. Barrier: First to second line of therapy is dominated by cheap, genericized topical drugs which create significant obstacles for novel drugs hoping to penetrate the market
    • 8.1.7. Barrier: The largest atopic dermatitis patient segment - mild disease - can be well-controlled on most forms of topical therapy
    • 8.1.8. Barrier: Pediatric sufferers are the largest patient group and pose a high bar in terms of safety for new products
    • 8.1.9. Barrier: The complexity of the multiple etiologies that lead to atopic dermatitis means that treatment outcomes with existing drugs are not universal across all patient groups
    • 8.1.10. Barrier: A significant proportion of patients experience disease remission in their early adolescent years and this may occur without drug therapy
  • 8.2. France
    • 8.2.1. Forecast
    • 8.2.2. Key Events
    • 8.2.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed Atopic Dermatitis Patients
    • 9.4.2. Percent Drug-treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Atopic Dermatitis
  • Table 2: Treatment Guidelines for Atopic Dermatitis
  • Table 3: Most Prescribed Drugs for Atopic Dermatitis by Severity in the Global Markets, 2013
  • Table 4: Referral Rates to a French Dermatologist, Split by Severity and Specialist Type, 2013
  • Table 5: Key Metrics Relating to the Diagnosis, Relapse and Remission Rates of Atopic Dermatitis in France in 2012
  • Table 6: Leading Treatments for Atopic Dermatitis, 2013
  • Table 7: Product Profile - Protopic
  • Table 8: Clinical Response Data of Protopic (0.03% and 0.1%) versus Vehicle Ointment at Week 12 from One Study in Pediatric Patients and Two Combined Studies in Adult Patients
  • Table 9: Protopic SWOT Analysis, 2013
  • Table 10: Product Profile - Elidel
  • Table 11: Combined Clinical Efficacy Results of Elidel versus Vehicle Cream at Week 6 from Two Phase III Studies
  • Table 12: Elidel SWOT Analysis, 2013
  • Table 13: Product Profile - Cyclosporine
  • Table 14: Cyclosporine SWOT Analysis, 2013
  • Table 15: Summary of Other Therapeutic Classes for Atopic Dermatitis, 2013
  • Table 16: Product Profile - Xolair
  • Table 17: Xolair SWOT Analysis, 2013
  • Table 18: Overall Unmet Needs in Atopic Dermatitis - Current Level of Attainment
  • Table 19: Clinical Unmet Needs in Atopic Dermatitis - Gap Analysis, 2013
  • Table 20: Late-Stage Atopic Dermatitis Pipeline, 2013
  • Table 21: Comparison of Therapeutic Classes in Development for Atopic Dermatitis, 2013
  • Table 22: Product Profile - Dupilumab
  • Table 23: Ongoing Clinical Trials of Dupilumab in Atopic Dermatitis Patients, as of September 2013
  • Table 24: Dupilumab SWOT Analysis, 2013
  • Table 25: Phase II and Phase I Atopic Dermatitis Pipeline, 2013
  • Table 26: Global Atopic Dermatitis Market - Drivers and Barriers, 2012-2022
  • Table 27: Sales Forecasts ($m) for Atopic Dermatitis in France, 2012-2022
  • Table 28: Key Event Impacting Sales for Atopic Dermatitis in France, 2012-2022
  • Table 29: Atopic Dermatitis Market in France - Drivers and Barriers, 2012-2022
  • Table 30: Key Launch Dates
  • Table 31: Key Patent Expiries
  • Table 32: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Immunologic Pathway Involved in Healthy, Acute Atopic Dermatitis, and Chronic Atopic Dermatitis Skin
  • Figure 2: Flow Chart of the Diagnosis and Management of Atopic Dermatitis
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Atopic Dermatitis, 2012-2022
  • Figure 4: Sales for Atopic Dermatitis in France by Drug Class, 2012-2022
Back to Top